Cullinan's zipalertinib shows 30.2% intracranial response rate in Phase 2 lung cancer trial
CGEM•Cullinan Therapeutics and Taiho Oncology announced Phase 2 REZILIENT2 results showing zipalertinib had a 30.2% intracranial response rate in patients with mutation-defined lung cancer and active brain metastases.
1. Trial results
Cullinan Therapeutics and Taiho Oncology said Phase 2 REZILIENT2 results showed zipalertinib activity against brain metastases in patients with non-small cell lung cancer harboring EGFR exon 20 insertions or other uncommon EGFR mutations. The treatment produced durable intracranial responses and was well tolerated, the companies said.
2. Presentation planned
The results are scheduled to be presented October 26, 2026, at the European Society for Medical Oncology Congress in Madrid.
